CD274 and head and neck squamous cell carcinoma: Another phase 1 study applied hypo-fractionated neoadjuvant RT with up to 3 × 6 Gy in combination with the PD-L1 inhibitor Durvalumab in 21 HPV negative HNSCC patients [32].